We provide you with 20 years of free, institutional-grade data for VERV stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of VERV. Explore the full financial landscape of VERV stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Dorval Allison | Sale | -3,350 | $4.15 | $13,903 | 2025-04-03 |
| Dorval Allison | Derivatives Exercise | 11,250 | 2025-04-03 | ||
| Lister Troy | Sale | -2,189 | $4.15 | $9,084 | 2025-04-03 |
| Lister Troy | Derivatives Exercise | 7,340 | 2025-04-03 | ||
| Politi Jason | Sale | -3,235 | $4.15 | $13,425 | 2025-04-03 |
| Politi Jason | Derivatives Exercise | 8,815 | 2025-04-03 | ||
| Ashe Andrew D. | Sale | -2,681 | $4.15 | $11,126 | 2025-04-03 |
| Ashe Andrew D. | Derivatives Exercise | 9,000 | 2025-04-03 | ||
| Kathiresan Sekar | Sale | -9,822 | $4.15 | $40,761 | 2025-04-03 |
| Kathiresan Sekar | Derivatives Exercise | 33,000 | 2025-04-03 | ||
| Nickerson Joan | Sale | -2,777 | $4.15 | $11,525 | 2025-04-03 |
| Nickerson Joan | Derivatives Exercise | 9,315 | 2025-04-03 | ||
| Dorval Allison | Sale | -555 | $5.64 | $3,130 | 2024-12-03 |
| Dorval Allison | Derivatives Exercise | 1,875 | 2024-12-03 | ||
| Kathiresan Sekar | Derivatives Exercise | 30,000 | 2024-07-02 | ||
| Politi Jason | Initial | 2024-06-28 | |||
| Lister Troy | Initial | 2024-06-25 | |||
| Ashe Andrew D. | Open Market Purchase | 76,000 | $6.26 | 2024-05-15 | |
| Nickerson Joan | Sale | -1,514 | $8.24 | $12,475 | 2024-04-03 |
| Nickerson Joan | Derivatives Exercise | 3,315 | 2024-04-03 | ||
| Yeshwant Krishna | Open Market Purchase | 1,800,000 | $10 | 2023-12-05 | |
| Dorval Allison | Sale | -554 | $11.45 | $6,343 | 2023-12-01 |
| Dorval Allison | Derivatives Exercise | 1,875 | 2023-12-01 | ||
| Nickerson Joan | Initial | 2023-02-23 | |||
| Bellinger Andrew | Derivatives Exercise | 36,000 | 2022-12-16 | ||
| Bellinger Andrew | Sale | -865 | $22.95 | $19,852 | 2022-12-02 |
| Dorval Allison | Sale | -554 | $22.1 | $12,243 | 2022-12-01 |
| Dorval Allison | Derivatives Exercise | 1,875 | 2022-12-01 | ||
| Yeshwant Krishna | Sale | -48,583 | $31.12 | $1,511,806 | 2022-11-08 |
| GV 2017 GP, L.L.C. | Sale | -48,583 | $31.12 | $1,511,806 | 2022-11-08 |
| GV 2017 GP, L.L.C. | Sale | -48,583 | $31.12 | $1,511,806 | 2022-11-08 |
| GV 2017 GP, L.L.C. | Sale | -78,220 | $34.78 | $2,720,132 | 2022-11-04 |
| GV 2017 GP, L.L.C. | Sale | -78,220 | $34.78 | $2,720,132 | 2022-11-04 |
| Yeshwant Krishna | Sale | -78,220 | $34.78 | $2,720,132 | 2022-11-04 |
| GV 2017 GP, L.L.C. | Sale | -85,659 | $37.91 | $3,246,999 | 2022-11-02 |
| GV 2017 GP, L.L.C. | Sale | -85,660 | $37.91 | $3,247,037 | 2022-11-02 |
| Yeshwant Krishna | Sale | -85,659 | $37.91 | $3,246,999 | 2022-11-02 |
| Bellinger Andrew | Sale | -10,000 | $39.9 | $399,000 | 2022-11-01 |
| Bellinger Andrew | Derivatives Exercise | 10,000 | 2022-11-01 | ||
| Kathiresan Sekar | Sale | -50,000 | $33.02 | $1,650,785 | 2022-10-05 |
| Kathiresan Sekar | Derivatives Exercise | 50,000 | 2022-10-05 | ||
| Bellinger Andrew | Sale | -60,000 | $34.67 | $2,079,960 | 2022-09-27 |
| Bellinger Andrew | Derivatives Exercise | 60,000 | 2022-09-27 | ||
| Ashe Andrew D. | Derivatives Exercise | 95,787 | 2022-08-29 |
The information provided in this report about VERV stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Verve Therapeutics(NASDAQ:VERV) 
Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States.
Share this website to your friends